A Study of Xeloda (Capecitabine) in Combination With XELOX (Oxaliplatin) in Patients With Metastatic Nasopharyngeal Cancer.
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of Xeloda + oxaliplatin when given
as first line treatment for patients with metastatic nasopharyngeal cancer. Patients will
receive Xeloda (1000mg/m2 bid orally from day 1 to day 14, followed by a rest period of 7
days) plus oxaliplatin (130mg/m2 iv infusion on day 1 of each 21 day cycle) for 6-8 cycles.
The anticipated time on study treatment is until disease progression, and the target sample
size is <100 individuals.